2024
Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regressionRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial management
2023
Prostate cancer disparities among American Indians and Alaskan Natives in the United States
Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenAlaska Native patientsCancer-specific mortalityGleason scoreNative patientsDefinitive treatmentWhite patientsProstate cancerTreatment accessAlaska NativesProvider densityHigher prostate-specific antigenAdvanced prostate cancerPatterns of careExternal beam radiationAmerican IndiansProstate cancer disparitiesCounty-level demographicsHealth policy interventionsLower ratesMultivariable adjustmentBaseline characteristicsPathologic factorsWorse survival